Evaluation of renal masses with CEST MRI : Protocol optimization and preliminary results
Magnetic Resonance in Medicine · 2025
DOI: 10.1002/mrm.30641 ↗At a glance
Studienprotokoll in Magnetic Resonance in Medicine, 2025. Written by Xiaojing Wang and 11 co-authors. Institution: Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Major MEDLINE topics: Kidney Neoplasms, Magnetic Resonance Imaging, Carcinoma, Renal Cell, Kidney. Cited 5 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIH HHS, NCI NIH HHS, NIBIB NIH HHS.
Abstract (original language)
Purpose
This study investigates the application of CEST MRI in human kidneys, with the overarching goal of developing CEST MRI for renal mass characterization. Here, the focus is on the development of a protocol and the proof‐of‐principle evaluation of CEST for the characterization of clear cell renal cell carcinoma (ccRCC).
Methods
Ten healthy volunteers and five patients diagnosed with ccRCC underwent CEST MRI scans at 3 T. The sequence performance was characterized in healthy volunteers and tested using three saturation power levels, B 1rms = 0.7, 1.2, and 1.6 μT. We compared the magnetization transfer ratio asymmetry (MTR asym ) values at 1.0, 2.0, and 3.5 ppm between the kidney cortex of healthy volunteers and the cortex/renal masses of renal cell carcinoma (RCC) patients. We also investigated the correlation of CEST with tumor characteristics, such as volume, necrosis percentage, and histopathological grade.
Results
Significant differences in MTR asym values were observed between ccRCC tumor regions and healthy kidney cortex in all three compared frequency offset ranges ( p < 0.05). At the same time, MTR asym values in the cortex of the contralateral kidney in RCC patients were not significantly different when compared with the values of healthy kidney cortex values ( p > 0.7).
Conclusion
CEST MRI demonstrates considerable potential as a non‐invasive imaging tool for the characterization of renal masses.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Philips Innovative Technologies, Hamburg, Germany.
- Philips, Cambridge, Massachusetts, USA.
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Internal Medicine and Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID profiles: Ananth Madhuranthakam, Durga Udayakumar, Elena Vinogradov
Funding
- NIH HHS
- NCI NIH HHS
- NIBIB NIH HHS
- National Institutes of Health
Cite
APA
Wang, X., Keupp, J., Dimitrov, I. E., Madhuranthakam, A., Udayakumar, D., Taherzadeh, M., Albayrak, E., Moe, O. W., Kapur, P., Lenkinski, R. E., Pedrosa, I., & Vinogradov, E. (2025). Evaluation of renal masses with CEST MRI : Protocol optimization and preliminary results. Magnetic Resonance in Medicine. https://doi.org/10.1002/mrm.30641
Vancouver
Wang X, Keupp J, Dimitrov IE, Madhuranthakam A, Udayakumar D, Taherzadeh M, et al. Evaluation of renal masses with CEST MRI : Protocol optimization and preliminary results. Magnetic Resonance in Medicine. 2025. doi:10.1002/mrm.30641
BibTeX
@article{Wang2025,
author = {Wang, Xiaojing and Keupp, Jochen and Dimitrov, Ivan E and Madhuranthakam, Ananth and Udayakumar, Durga and Taherzadeh, Mahsa and Albayrak, Emin and Moe, Orson W and Kapur, Payal and Lenkinski, Robert E and Pedrosa, Ivan and Vinogradov, Elena},
title = {Evaluation of renal masses with CEST MRI : Protocol optimization and preliminary results},
journal = {Magnetic Resonance in Medicine},
year = {2025},
doi = {10.1002/mrm.30641}
}
EUVIMED